ChiCTR2600121441 版本V1.0 版本创建时间2026/03/31 09:00:46 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600121441 

最近更新日期:

Date of Last Refreshed on:

2026-03-31 09:00:34 

注册时间:

Date of Registration:

2026-03-31 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于多模态数据的早期预警评分系统在入院管理中心急危重症精准识别的应用研究

Public title:

Application Research of an Early Warning Scoring System Based on Multimodal Data in the Accurate Identification of Critically Ill Patients in the Admission Management Center

注册题目简写:

多数据预警:帮医院更快揪出高危病人

English Acronym:

Multi-data Early Warning: Helping Hospitals Identify High-risk Patients Faster

研究课题的正式科学名称:

基于多模态数据的早期预警评分系统在入院管理中心急危重症精准识别的应用研究

Scientific title:

Application Research of an Early Warning Scoring System Based on Multimodal Data in the Accurate Identification of Critically Ill Patients in the Admission Management Center

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

苗淑敏 

研究负责人:

苗淑敏 

Applicant:

Miao Shumin 

Study leader:

Miao Shumin 

申请注册联系人电话:

Applicant telephone:

+86 137 5764 9739

研究负责人电话:

Study leader's telephone:

+86 576 8885 2720

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

190456436@qq.com

研究负责人电子邮件:

Study leader's E-mail:

190456436@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省台州市椒江区凤凰铂金9栋

研究负责人通讯地址:

台州市椒江区市府大道东581号

Applicant address:

Building 9, Fenghuang Bojin, Jiaojiang District, Taizhou City, Zhejiang Province

Study leader's address:

No, 581 East of Shifu Avenue Jiaojiang District, Taizhou City, Zhe Jiang Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

台州市立医院

Applicant's institution:

taizhou municipal hospital

研究负责人所在单位:

台州市立医院

Affiliation of the Leader:

Taizhou Municipal Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KTYJ202500184

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

台州市立医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Taizhou Municipal Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-09-24 00:00:00

伦理委员会联系人:

汪佳兵

Contact Name of the ethic committee:

Wang Jiabing

伦理委员会联系地址:

台州市椒江区市府大道东581号

Contact Address of the ethic committee:

No, 581 East of Shifu Avenue Jiaojiang District, Taizhou City, Zhe Jiang Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 576 8885 8566

伦理委员会联系人邮箱:

Contact email of the ethic committee:

wangjiabing9205@163.com

研究实施负责(组长)单位:

台州市立医院

Primary sponsor:

Taizhou Municipal Hospital

研究实施负责(组长)单位地址:

台州市椒江区市府大道东581号

Primary sponsor's address:

No, 581 East of Shifu Avenue Jiaojiang District, Taizhou City, Zhe Jiang Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江省

市(区县):

Country:

China

Province:

Zhejiang

City:

单位(医院):

台州市立医院

具体地址:

台州市椒江区市府大道东581号

Institution
hospital:

Taizhou Municipal Hospital

Address:

No, 581 East of Shifu Avenue Jiaojiang District, Taizhou City, Zhe Jiang Province

经费或物资来源:

2025 年度浙江省卫生健康行业科技计划

Source(s) of funding:

2025 Zhejiang Provincial Health Science and Technology Program

Target disease:

Multidisciplinary Diseases

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机交叉对照 

Study design:

Cross-over 

研究目的:

一是多模态数据收集与智能整合; 二是基于动态分层的预警评分系统临床应用; 三是临床效果、可行性与卫生经济学评估。  

Objectives of Study:

Collection and intelligent integration of multimodal data Clinical application of an early warning scoring system based on dynamic stratification Evaluation of clinical efficacy, feasibility and health economics

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄≥18岁; 2.通过急诊、门诊或院际转诊途径入住入院管理中心的患者;

Inclusion criteria

1. Aged 18 years or older; 2. Patients admitted to the Admission Management Center via emergency department, outpatient service or inter-hospital referral;

排除标准:

1. 已明确诊断为终末期疾病患者; 2. 入院前已接受重症监护治疗; 3. 院前心肺复苏后患者; 4. 妊娠患者; 5. 数据缺失超过30%者。

Exclusion criteria:

1. Patients with a confirmed diagnosis of end-stage diseases; 2. Patients who had received intensive care treatment prior to admission; 3. Patients after pre-hospital cardiopulmonary resuscitation; 4. Pregnant patients; 5. Subjects with missing data exceeding 30%.

研究实施时间:

Study execute time:

From 2026-01-01 00:00:00 To 2028-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-04-01 00:00:00 To 2027-05-31 00:00:00  

干预措施:

Interventions:

组别:

对照组

样本量:

565

Group:

Control group

Sample size:

干预措施:

先采用传统 MEWS 评分系统评估患者, 按照常规流程管理患者。 后采用多模态数据早期预警评分系统(MD-EWS)进行风险评估 + 分级干预

干预措施代码:

Intervention:

First, use the traditional MEWS scoring system to assess the patient and manage the patient according to standard procedures. Then, use the Multi-modal Data-based Early Warning Score (MD-EWS) for risk assessment and hierarchical intervention Risk assessment and hierarchical intervention using the Multi-modal Data-based Early Warning Score (MD-EWS)

Intervention code:

组别:

干预组

样本量:

565

Group:

Intervention group

Sample size:

干预措施:

先采用多模态数据早期预警评分系统(MD-EWS)进行风险评估 + 分级干预。 后采用采用传统 MEWS 评分系统评估患者, 按照常规流程管理患者。

干预措施代码:

Intervention:

First, use the Multi-modal Data-based Early Warning Score (MD-EWS) for risk assessment and hierarchical intervention. Then, use the traditional MEWS scoring system to evaluate patients and manage them according to routine procedures.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江省 

市(区县):

 

Country:

China 

Province:

Zhejiang 

City:

 

单位(医院):

台州市立医院 

单位级别:

三级乙等 

Institution
hospital:

Taizhou Municipal Hospital

Level of the institution:

Tertiary B

测量指标:

Outcomes:

指标中文名:

预警准确性指标

指标类型:

主要指标

Outcome:

Warning Accuracy Indicator

Type:

Primary indicator

测量时间点:

0,30分钟,60分钟

测量方法:

生命体征(心率、血压等):采用院内统一监护仪实时采集,每 15 分钟记录 1 次,异常值通过 Z-score 标准化处理。 等

Measure time point of outcome:

0,30m,60m

Measure method:

Vital signs (heart rate, blood pressure, etc.): Collected in real time using unified hospital monitors, recorded every 15 minutes, and outliers are processed through Z-score standardization.et al

指标中文名:

多模态数据贡献度指标

指标类型:

主要指标

Outcome:

Multimodal Data Contribution Indicator

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

医疗费用

指标类型:

次要指标

Outcome:

Medical expenses

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机数列的产生由多学科研究团队中的统计学专家或医学信息学专家负责,采用分层区组随机化方法生成

Randomization Procedure (please state who generates the random number sequence and by what method):

The generation of random sequences shall be undertaken by statisticians or medical informaticians within the multidisciplinary research team, using a stratified block randomization method.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

开放标签

Blinding:

Open-label study

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本研究的数据采集和管理围绕 “标准化、全流程、高安全” 原则设计,覆盖数据收集、预处理、存储、质控全环节,确保数据真实、完整、合规

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The data collection and management of this study are designed around the principles of "standardization, full-process coverage, and high security", covering all links including data collection, preprocessing, storage, and quality control to ensure the data is authentic, complete, and compliant.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2026-03-31 09:00:34